The Effects of Proresolution of Ellagic Acid in an Experimental Model of Allergic Airway Inflammation

Figure 2

Ellagic acid demonstrates therapeutic anti-inflammatory activity on the resolution phase in the experimental airways allergic inflammation model. Mice received ellagic acid (10 mg/kg, p.o.), dexamethasone (1 mg/kg, s.c.), or vehicle (water, p.o.) after ovalbumin challenge at 18, 19, and 20 days (see Section 2) and were euthanized on 21 or 25 days and cells in bronchoalveolar lavage were counted (a). BALF cells and leukocytes subset at 21 days (b); BALF cells and leukocytes subset at 25 days (c). One group of animals received vehicle (p.o.) only (control group). EPO concentration in the lung at 21 day (d). The resolution interval (𝑅_𝑖) (e). Results represent the mean ± SEM, of two or more independent experiments with four mice per group per experiment. ^∗𝑃<0.05 compared with control group; ^#𝑃<0.05 compared with ovalbumin + vehicle group.

(a)

(b)

(c)

(d)

(e)